Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-17 pm EDT			5-day change	1st Jan Change
108.00 ^USD	-2.55%		-4.42%	+16.92%

Jun. 13	Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11:20 AM
Jun. 11	Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says	MT

US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination

Published on 06/10/2025 at 09:59

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Gilead Sciences, Inc.

Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11:20 AM	Jun. 13
Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says	Jun. 11	MT
RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating	Jun. 11	MT
US FDA pauses Gilead trials testing experimental HIV pill combination	Jun. 10	RE
US FDA pauses Gilead trials testing experimental HIV pill combination	Jun. 10	RE
Gilead : FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182	Jun. 10	DJ
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials	Jun. 10	MT
Gilead Says FDA Placed Clinical Hold On HIV Treatment Trials Of GS-1720 And/Or GS-4182	Jun. 10	RE
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination	Jun. 10	RE
Gilead Sciences, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 11:05 AM	Jun. 04
Gilead Sciences Insider Sold Shares Worth $1,104,193, According to a Recent SEC Filing	Jun. 03	MT
DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating	Jun. 02	MT
Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study	Jun. 02	MT
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial	Jun. 02	RE
Gilead's CAR-T cell therapy shows promise in deadly brain cancer	Jun. 01	RE
Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer	May. 31	RE
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer	May. 31	CI
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty	May. 30	RE
Regeneron shares slide on mixed trial data for smoker's lung drug	May. 30	RE
Regeneron shares slide on mixed trial data for smoker's lung drug	May. 30	RE
Gilead Sciences, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 02:30 PM	May. 29
Gilead Sciences Insider Sold Shares Worth $3,010,564, According to a Recent SEC Filing	May. 23	MT
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy	May. 23	CI
Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial	May. 23	MT
ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors	May. 23	RE

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company